,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['mbc', 'improve ', 'breast', 'destiny-breast04']
 destiny-breast04: standing ovation more than deserved . t-dxd showed to improve pfs and os in pretreated her2-low (1+ and 2+ ish -) #mbc patients vs tpc. "the adc era has just begun also in her2-low bc". these results speak for themselves. #asco22 #bcareporter 